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 subsequent careful analysis (for example, 
by region, ethnic background, and medical 
system) would lead to better identifi cation 
of true genotype – phenotype correlations, 
but also genetic and environmental modi-
fi ers responsible for the variability in dis-
ease expression. In this regard, the current 
collaboration between the pan-European 
Hyperoxaluria Consortium (OxalEurope) 
and the Mayo Clinic Hyperoxaluria Center 
(USA) will help by creating a database with 
significant numbers for genotype –
 phenotype studies (an estimated   >  600 PH 
cases worldwide), as well as for the devel-
opment of predictive models. 
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 Endocrine dysfunction is common in 
patients with chronic kidney disease 
(CKD), especially those near end-stage 
renal disease and those on renal replace-
ment. One of the dysfunctions is the 
growth hormone – insulin-like growth 
factor-1 (GH – IGF-1) axis. 
 Figure 1 is a schematic representation 
of the physiology of the GH – IGF-1 axis, 
showing that the hypothalamus produces 
GH-releasing hormone (GHRH) and 
somatostatin to, respectively, stimulate 
and suppress GH secretion. GH acts on 
many target tissues, but most importantly, 
it stimulates the liver to synthesize IGF-1, 
which accounts for most of the circulating 
IGF-1. GH also stimulates many target tis-
sues to produce IGF-1 that acts locally in 
an autocrine / paracrine fashion. It appears 
that the locally made IGF-1 is as impor-
tant as that produced by the liver, because 
liver IGF-1 knockout mice grew normally. 
IGF-1 receptors are present ubiquitously 
in almost all tissue, including cartilage, 
bone, muscle, liver, kidney, and the nerv-
ous system. In circulation, IGF-1 is bound 
to six binding proteins; 80 % of which is 
IGF-binding protein-3 (IGFBP-3), which 
is the active moiety. IGF-1 bound to other 
binding proteins is physiologically inhib-
itory with regard to its function. Th e GH – 
IGF-1 axis regulates statural growth and 
body composition, the latter through 
enhanced protein synthesis and lipolysis. 
 Th e dysfunction in the GH – IGF-1 axis 
in CKD patients is not due to abnormal 
central hypothalamic – pituitary regulation 
but lies in tissue resistance to both mole-
cules. Th e circulating level of GH is high 
and that of IGF-1 either normal or low; a 
normal IGF-1, in the presence of high GH, 
suggests that the liver is not responding 
adequately to the GH. In the liver and 
many target tissues where GH and IGF-1 
exert their physiological action, there is a 
post-receptor defect in the phosphoryla-
tion of various tyrosine kinases along the 
JAK – STAT transduction pathway. 1,2 
 The most prominent clinical conse-
quence of the GH – IGF-1 axis abnormality 
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 Niemczyk  et al. treated predialysis chronic kidney disease patients with 
a new growth hormone-releasing hormone agonist, AKL-0707, and 
noted important changes in body composition characterized by an 
increase in fat-free mass, a modest rise in bone mineral content, and a 
reduction in fat mass. These changes were accompanied by a reduction 
in both serum urea nitrogen and normalized protein nitrogen 
appearance rate, while dietary protein intake was unchanged. 
Importantly, there were no serious adverse events. 
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in CKD patients is impaired linear bone 
growth in children, which is underscored 
by the unequivocal catch-up growth 
observed with pharmacological doses of 
recombinant human GH (rhGH). 3 In 
adults, there is, however, no single mani-
festation that can be attributed to the dys-
function of this system, except for the 
notion that malnutrition observed in CKD 
patients may be related to excessive catab-
olism that could be ameliorated by GH. In 
the past two decades, there have been mul-
tiple studies and trials using rhGH in adult 
CKD patients, with equivocal and 
 sometimes confl icting results. Garibotto 
 et al. , using forearm [ 3 H]phenylalanine 
fl ux technique, found that 6 weeks of rhGH 
treatment resulted in an increase in muscle 
protein synthesis and a decrease in negative 
protein balance in the post-absorptive state 
in hemodialysis patients. 4 Kopple and col-
leagues found that a 2-week subcutaneous 
administration of rhGH to hemodialysis 
patients led to a strong and sustained pos-
itive nitrogen balance. 5 By contrast, Kotz-
mann and associates wrote that after 3 
months of rhGH therapy, hemodialysis 
patients showed no change in their nutri-
tional and anthropometric parameters 
even though serum IGF-1 levels were 
 signifi cantly raised. 6 
 Niemczyk  et al. 7 (this issue) now 
report that a 4-week course of treatment 
with a newly discovered GHRH super-
agonist, AKL-0707, resulted in an 
impressive improvement in body com-
position. Th is is a phase II randomized, 
placebo-controlled, double-blind 
effi  cacy / toxicity study in which 26 sub-
jects completed the protocols; 12 were 
given the active agent, and 14 were given 
placebo. Th ose who received the active 
medication showed a gain in body weight 
and, as demonstrated by dual-energy X-
ray absorptiometry, an unequivocal 
increase in fat-free mass, a modest rise 
in bone mineral content, and, most inter-
estingly, a reduction in fat mass. Th ere-
fore, the observed rise in body weight 
was entirely due to an increase in lean 
muscle mass. By comparison, weight and 
body composition remained unchanged 
in those who received placebo. Th is is 
particularly remarkable in that the study 
subjects were in their 60  s, a time of life 
when aging tends to favor fat accumula-
tion and reduced muscle mass; thus, it is 
almost like reversal of the aging process. 
The net gain in lean body mass was 
accompanied by a decrease in serum urea 
nitrogen concentration and a reduction 
in normalized protein nitrogen appear-
ance rate as derived from 24-hour urine 
urea nitrogen excretion. It is noteworthy 
that these changes in urea nitrogen pro-
file occurred in the presence of an 
unchanged dietary protein intake. 
 Th e authors attribute these remarkable 
anabolic eff ects to the ability of AKL-0707 
to greatly stimulate GH secre tion, as 
serum GH level and GH secretion rate, 
represented by GH area under the curve, 
were both strikingly increased whereas no 
increment was seen in the placebo group. 
Additionally, AKL-0707 also signifi cantly 
increased serum IGF-1 levels and com-
pletely normalized the circulating IGFBP 
profi le characterized by an increase in 
IGFBP-3 and a reduction in IGFBP-1; 
these changes prolonged the half-life of 
IGF-1 and enhanced its local action. 
 AKL-0707 is an analog of human 
GHRH resulting from substitution of its 
levo-amino acids at Ala 2 , Tyr 10 , Ala 15 , and 
Lys 22 by dextro-amino acids of hGHRH
(1 – 29)NH 2 ; this dextro-isoform amino 
acid – substituted molecule increased its 
affi  nity to bind human GHRH receptors 
 in vitro by an incredible magnitude of 
900-fold, thus the name super-agonist. 
 It is important to mention here that 
ghrelin is another naturally occurring 
peptide that could stimulate GH release. 
Th is point is interesting because ghrelin, 
touted as the  ‘ hungry hormone, ’ has gen-
erated lots of interest as a potential thera-
peutic agent to treat malnutrition. It not 
only enhances feeding but should also 
stimulate GH secretion like a GHRH ago-
nist. Th e study by Niemczyk  et al. 7 did not 
measure ghrelin levels, so we do not know 
whether ghrelin would be suppressed by 
this new agonist. 
 One disappointing aspect of this study is 
the failure to demonstrate improved pro-
tein synthesis with the whole-body leucine 
fl ux technique, as increased protein syn-
thesis is the hallmark of GH-induced anab-
olism. Perhaps regional kinetics would be 
the more appropriate technique to demon-
strate changes in amino acid turnover at 
the muscle level. We have observed distinct 
differences between whole-body and 
regional amino acid kinetics in CKD 
 Figure 1  |  A diagram of GH – IGF-1 axis physiology. Solid lines indicate stimulatory effects; dotted 
lines indicate inhibitory effects. Xs represent steps along the axis where chronic kidney disease 
patients showed defective function. AKL-0707 is the new GH-releasing hormone super-agonist. 
GHRH, growth hormone – releasing hormone; IGF-1, insulin-like growth factor 1.  
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patients. 8 Measurement of amino acid 
kinetics in the fed state would be another 
method to better document enhanced pro-
tein synthesis; that would involve the 
administration of two isotopes, one given 
orally and the other intravenously. Th is 
study also does not explain the mechanism 
of how excessive GH overcomes target tis-
sue resistance; it is not unlike giving large 
doses of insulin to patients with type 2 dia-
betes. We also do not know whether the 
 hormonal changes could be translated to 
improved physical performance. 
 Why, one might ask, should we be inter-
ested in this new analog of GHRH when 
rhGH and IGF-1 are available and have 
been used with some success? First, both 
GH and IGF-1 exert a negative-feedback 
eff ect on the hypothalamus and the pitui-
tary and thus downregulate endogenous 
production of these two hormones. 
In using a GHRH agonist, one can keep 
the endogenous production upregulated. 
Second, treatment with a GHRH agonist 
maintains the pulsatile nature of GH 
secretion, and this rhythmicity is of 
important physiological consequence. 
Th ird, no previous studies using rhGH 
had documented any solid increase in fat-
free mass in CKD patients; most reports 
showed only short-term eff ects such as 
enhanced protein synthesis during isotope 
infusion, increased amino acid uptake, or 
positive nitrogen balance. 
 Niemczyk  et al. 7 found no serious 
adverse events with the new agonist. 
However, there are many potential side 
effects from prolonged GH therapy, 
including fl uid retention, arthralgia, car-
pal tunnel syndrome, hyperglycemia, and 
maybe some features of acromegaly. Th e 
new agonist, in this study, was found to 
increase both fasting insulin and glucose, 
suggesting insulin resistance. While GH 
confers a state of insulin resistance, 9 IGF-1 
enhances glucose clearance and did not 
increase serum insulin. 10 Th us, it appears 
that, in the study by Niemczyk  et al. , 7 GH 
exerted a dominant effect on glucose 
metabolism. It is comforting to know that 
the hormonal changes returned to baseline 
level aft er discontinuation of treatment. 
 If further studies confi rm the same ana-
bolic phenomenon in CKD patients, the 
new drug could conceivably be tried in 
many other population groups. 
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 During mid-embryogenesis (embryonic 
day 10.5 of mouse development), the ure-
teric bud emanates from the nephric duct 
and contacts the adjacent metanephric 
mesenchyme. Th is process constitutes the 
fi rst step of defi nitive nephrogenesis. Th e 
ureteric bud undergoes branching mor-
phogenesis and eventually gives rise to the 
ureter, the renal pelvis, and the collecting 
duct system. The metanephric mesen-
chyme contains committed progenitors 
that, as a result of interactions with the 
ureteric bud, diff erentiate to generate the 
nephron. Th ese processes are critical for 
kidney development and, when perturbed, 
 1 Experimental and Clinical Research Center, 
Charit é – Universit ä tsmedizin Berlin, Max Delbr ü ck 
Center for Molecular Medicine ,  Berlin ,  Germany 
 Correspondence: Kai M. Schmidt-Ott, 
Max Delbr ü ck Center for Molecular Medicine, 
Robert-R ö ssle-Strasse 10, 13125 Berlin, Germany. 
E-mail:  kai.schmidt-ott@mdc-berlin.de 
 ROCK inhibition facilitates tissue 
reconstitution from embryonic 
kidney cell suspensions 
 Kai M.  Schmidt-Ott 1 
 Explanted embryonic kidney tissues, when placed in organ culture, 
recapitulate key aspects of nephron formation. Yet attempts to 
dissociate these tissues into single cells to make them more accessible 
for genetic manipulation and tissue recombination have been 
disappointing. Now it is reported that inhibitors of Rho-associated 
kinase (ROCK) facilitate tissue reconstitution and nephron 
differentiation from single-cell suspensions of the embryonic kidney. 
This finding illustrates an unexpected potential for self-organization in 
these cells and introduces a window of single-cell accessibility to the 
organ culture system. 
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